Drug Profile
GI 111924
Latest Information Update: 10 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antineoplastics
- Mechanism of Action Steroid 17-alpha-hydroxylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 24 Aug 1999 Discontinued-I for Prostate cancer in United Kingdom (Unknown route)
- 08 Sep 1998 No-Development-Reported for Prostate cancer in United Kingdom (Unknown route)
- 29 Aug 1996 Phase-I clinical trials for Prostate cancer in United Kingdom (Unknown route)